News Sentiment

CTMX sentiment intelligence

CytomX Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.01 Week of 12 Jun 2026
Weighted tone 60/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+0.3% over one week, -16.6% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 0.3% Price digesting
Trend fit Trend inactive -16.6% over four weeks
Fair value 38.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 29
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 9
simplywall.st 5
Insider Monkey 3
TradingKey 3
Simply Wall Street 3
Investing.com 3
TradingView 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 19
Analyst action 5
Deals and strategy 4
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-53 of 53
Simply Wall Street Direct company coverage

Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher

Analysts have significantly upgraded revenue forecasts for CytomX Therapeutics, Inc. for 2026, with estimates rising from US$22 million to US$35 million, and reducing projected per-share losses. Despite the improved outlook, analysts have maintained their price target of US$13.00

Tone
Positive 67/100
Event
Earnings
Published
13 May 2026 11:39
Source
Simply Wall Street
Simply Wall Street Direct company coverage

CytomX Therapeutics (NasdaqGS:CTMX) Stock Forecast & Analyst Predictions

CytomX Therapeutics (CTMX) is forecast to grow earnings by 2.4% and revenue by 36.5% annually. Recent analyst revisions for 2026 revenue have increased by 52%, with expected loss reductions. Despite positive clinical data for its lead programs, the company faces risks such as sha

Tone
Positive 65/100
Event
Earnings
Published
12 May 2026 15:10
Source
Simply Wall Street
Investing.com Direct company coverage

Earnings call transcript: CytomX Therapeutics Q1 2026 beats EPS forecast

CytomX Therapeutics reported strong Q1 2026 results, surpassing EPS and revenue forecasts, yet its stock declined in after-hours trading. The company's lead candidate, Varseta-M, an EpCAM-targeting ADC, shows promising clinical results in late-line metastatic colorectal cancer, w

Tone
Neutral 50/100
Event
Earnings
Published
12 May 2026 14:08
Source
Investing.com